IP Library › Granted Patent US 10,835,719
Granted Patent B2
US 10,835,719 · App. 15/674,144 · Granted Nov 17, 2020

Drug releasing coatings for medical devices

Inventor: Lixiao Wang (Medina, MN)
Assignee: Lutonix, Inc.
A61M25/10A61F2/844A61F2/958A61K31/337A61K31/436A61L29/08A61L29/085A61L29/16A61L31/08A61L31/10A61L31/16A61K2300/00A61L2300/416A61L2300/428A61L2300/606A61L2300/608A61L2300/802A61M2025/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,835,719
App. No.
15/674,144
Granted
Nov 17, 2020
Kind
B2
Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

Claims (36)

1. A medical device for delivering a therapeutic agent to a tissue, the medical device comprising a coating layer overlying an exterior surface of the medical device, the coating layer consisting of a therapeutic agent and an additive, wherein:

the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, beta-lapachone,

biologically active vitamin D, and combinations thereof;

the additive is an anionic surfactant selected from the group consisting of aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, zinc stearate, sodium oleate, zinc oleate, potassium oleate, sodium stearyl fumarate, sodium lauroyl sarcosinate, and sodium myristoyl sarcosinate.

2. The medical device of claim 1 , wherein the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof.

3. The medical device of claim 1 , wherein the therapeutic agent is paclitaxel.

4. The medical device of claim 1 , wherein the anionic surfactant is selected from the group consisting of aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, and zinc stearate.

5. The medical device of claim 1 , wherein the additive is magnesium stearate.

6. The medical device of claim 1 , wherein:

the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof; and

the anionic surfactant is selected from the group consisting of aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, and zinc stearate.

7. The medical device of claim 1 , wherein:

the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, or combinations thereof; and

the additive is magnesium stearate.

8. The medical device of claim 1 , wherein:

the therapeutic agent is paclitaxel; and

the anionic surfactant is selected from the group consisting of aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, and zinc stearate.

9. The medical device of claim 1 , wherein: the therapeutic agent is paclitaxel; and the additive is magnesium stearate.

10. The medical device of claim 1 , wherein:

the medical device is a balloon catheter;

the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof; and

the anionic surfactant is selected from the group consisting of aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, and zinc stearate.

11. The medical device of claim 1 , wherein:

the medical device is a balloon catheter;

the therapeutic agent is paclitaxel; and

the anionic surfactant is selected from the group consisting of aluminum stearate, sodium stearate, calcium stearate, magnesium stearate, and zinc stearate.

12. The medical device of claim 1 , wherein:

the medical device is a balloon catheter;

the therapeutic agent is paclitaxel; and

the additive is magnesium stearate.

13. The medical device of claim 1 , wherein the medical device includes one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, a laser catheter, an atherectomy device, a debulking catheter, a stent, a filter, a stent graft, a covered stent, a patch, a wire, or a valve.

14. The medical device of claim 1 , wherein the medical device includes one of a balloon catheter, a scoring balloon catheter, a stent, or a stent graft.

15. The medical device of claim 1 , wherein the medical device is a balloon catheter.

16. The medical device of claim 1 , wherein the concentration of the therapeutic agent in the layer is from 1 ug/mm 2 to 20 ug/mm 2 .

17. The medical device of claim 1 , wherein the medical device further comprises a top layer overlying the surface of the coating layer overlying the exterior surface of the medical device to reduce loss of drug during transit through a body to the tissue.

18. The medical device of claim 1 , wherein the tissue includes tissue of one of coronary vasculature, peripheral vasculature, cerebral vasculature, esophagus, airways, sinus, trachea, colon, biliary tract, urinary tract, prostate, or brain passages.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2020
From: WANG, LIXIAO
To: LUTONIX, INC.
Reel/Frame 053513/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2020
From: WANG, LIXIAO
To: LUTONIX, INC.
Reel/Frame 053513/0437 →
Continuity (15)
Continuation 15067739 · Mar 11, 2016
Continuation 14683612 · Apr 10, 2015
Continuation 13846143 · Mar 18, 2013
Continuation 12731835 · Mar 25, 2010
Continuation In Part 12121986 · May 16, 2008
Continuation In Part 11942452 · Nov 19, 2007
Provisional Application 60860084 · Nov 20, 2006
Provisional Application 60880742 · Jan 17, 2007
Provisional Application 60897427 · Jan 25, 2007
Provisional Application 60903529 · Feb 26, 2007
Provisional Application 60904473 · Mar 2, 2007
Provisional Application 60926850 · Apr 30, 2007
Provisional Application 60981380 · Oct 19, 2007
Provisional Application 60981384 · Oct 19, 2007
Related Publication 20180021553A1 · Jan 25, 2018